Sign In
Buy TRDA
$6.58
-0.0600 (-0.90%)
At Close: Jun 03, 2026
Entrada Therapeutics to Present at Upcoming Investor Conferences
07:00am, Tuesday, 29'th Aug 2023
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
07:00am, Thursday, 10'th Aug 2023
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates
09:55am, Tuesday, 08'th Aug 2023
Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.74 per share a year ago.
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
07:00am, Tuesday, 08'th Aug 2023
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the United Kingdom in September 2023 –
Entrada Therapeutics: Early Stage But Interesting
06:39pm, Thursday, 03'rd Aug 2023
Entrada Therapeutics is developing endosomal escape vehicles (EEV) to deliver oligonucleotides for neuromuscular diseases. Despite having no clinical data, the company has a market cap of nearly $600m
New Strong Buy Stocks for July 21st
08:27am, Friday, 21'st Jul 2023
TRDA, LPRO, TBBK, BMTX and MOTS have been added to the Zacks Rank #1 (Strong Buy) List on July 21, 2023.
Entrada (TRDA) Surges on Collaboration With Vertex for DMI
03:03pm, Friday, 09'th Dec 2022
Entrada (TRDA) gains from its collaboration deal with Vertex to discover and develop Endosomal Escape Vehicle (EEV) therapeutics for DM1.
Entrada Therapeutics shares jump on collaboration with Vertex
08:24am, Thursday, 08'th Dec 2022
Shares of Entrada Therapeutics Inc. TRDA, +3.20% rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. VRTX, +1.85% that aims to develop trea
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
07:00am, Tuesday, 30'th Aug 2022
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
07:00am, Wednesday, 06'th Jul 2022
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap
Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday
01:00pm, Tuesday, 07'th Jun 2022
We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halte
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
07:00am, Wednesday, 01'st Jun 2022
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escap
5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20
09:48am, Monday, 18'th Apr 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
U.S. IPO Weekly Recap: Semiconductors And Energy Storage Lead A Spooky 14 IPO Week
11:43pm, Saturday, 30'th Oct 2021
The IPO market remained active this past week as 13 IPOs raised $6.3 billion. SPAC activity kept steady with 13 blank check IPOs raising $2.1 billion.
